Middle East Respiratory Syndrome Coronavirus NS4b Protein Inhibits Host RNase L Activation by Thornbrough, Joshua M. et al.
Middle East Respiratory Syndrome Coronavirus NS4b Protein Inhibits
Host RNase L Activation
Joshua M. Thornbrough,a* Babal K. Jha,b* Boyd Yount,c Stephen A. Goldstein,a Yize Li,a Ruth Elliott,a Amy C. Sims,c Ralph S. Baric,c,d
Robert H. Silverman,b Susan R. Weissa
Department of Microbiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USAa; Department of Cancer Biology, Lerner
Research Institute, Cleveland Clinic, Cleveland, Ohio, USAb; Department of Epidemiologyc and Department of Microbiology and Immunology,d University of North
Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
* Present address: Joshua M. Thornbrough, Adelphi Research Global, Doylestown, Pennsylvania, USA; Babal K. Jha, Translational Hematology & Oncology Research, Taussig Cancer
Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
ABSTRACT Middle East respiratory syndrome coronavirus (MERS-CoV) is the first highly pathogenic human coronavirus to
emerge since severe acute respiratory syndrome coronavirus (SARS-CoV) in 2002. Like many coronaviruses, MERS-CoV carries
genes that encode multiple accessory proteins that are not required for replication of the genome but are likely involved in
pathogenesis. Evasion of host innate immunity through interferon (IFN) antagonism is a critical component of viral pathogene-
sis. The IFN-inducible oligoadenylate synthetase (OAS)-RNase L pathway activates upon sensing of viral double-stranded RNA
(dsRNA). Activated RNase L cleaves viral and host single-stranded RNA (ssRNA), which leads to translational arrest and subse-
quent cell death, preventing viral replication and spread. Here we report that MERS-CoV, a lineage C Betacoronavirus, and re-
lated bat CoVNS4b accessory proteins have phosphodiesterase (PDE) activity and antagonize OAS-RNase L by enzymatically
degrading 2=,5=-oligoadenylate (2-5A), activators of RNase L. This is a novel function for NS4b, which has previously been re-
ported to antagonize IFN signaling. NS4b proteins are distinct from lineage A Betacoronavirus PDEs and rotavirus gene-encoded
PDEs, in having an amino-terminal nuclear localization signal (NLS) and are localized mostly to the nucleus. However, the ex-
pression level of cytoplasmic MERS-CoVNS4b protein is sufficient to prevent activation of RNase L. Finally, this is the first re-
port of an RNase L antagonist expressed by a human or bat coronavirus and provides a specific mechanism by which this occurs.
Our findings provide a potential mechanism for evasion of innate immunity byMERS-CoV while also identifying a potential
target for therapeutic intervention.
IMPORTANCE Middle East respiratory syndrome coronavirus (MERS-CoV) is the first highly pathogenic human coronavirus to
emerge since severe acute respiratory syndrome coronavirus (SARS-CoV). MERS-CoV, like other coronaviruses, carries genes
that encode accessory proteins that antagonize the host antiviral response, often the type I interferon response, and contribute to
virulence. We found that MERS-CoVNS4b and homologs from related lineage C bat betacoronaviruses BtCoV-SC2013 (SC2013)
and BtCoV-HKU5 (HKU5) are members of the 2H-phosphoesterase (2H-PE) enzyme family with phosphodiesterase (PDE) ac-
tivity. Like murine coronavirus NS2, a previously characterized PDE, MERS NS4b, can antagonize activation of the OAS-RNase L
pathway, an interferon-induced potent antiviral activity. Furthermore, MERS-CoVmutants with deletion of genes encoding ac-
cessory proteins NS3 to NS5 or NS4b alone or inactivation of the PDE can activate RNase L during infection of Calu-3 cells. Our
report may offer a potential target for therapeutic intervention if NS4b proves to be critical to pathogenesis in in vivomodels of
MERS-CoV infection.
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Middle East respiratory syndrome coronavirus (MERS-CoV)infections range from mild upper respiratory infections to
severe acute respiratory distress syndrome, with a global case fa-
tality rate of 36% (1, 2). MERS-CoV has predominantly affected
theKingdomof Saudi Arabia and neighboring countries with spo-
radic cases arising in Europe and North America as the result of
travel to and from the Middle East (3). A recent outbreak of
MERS-CoV in South Korea has raised the specter that unrecog-
nized infections combined with potential superspreaders may
pose a much greater risk of significant travel-associated outbreaks
of MERS-CoV than previously suspected, particularly in health
care settings (4, 5). The lethality of MERS-CoV and the ease of
global travel necessitate further study and understanding of the
mechanisms of MERS-CoV pathogenesis.
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MERS-CoV, a lineage C Betacoronavirus, has a 30-kb positive-
sense single-stranded RNA (ssRNA) genome. As with all CoVs,
the first 5= two-thirds of the genome consists of the replicase en-
coded in open reading frame 1a (ORF1a) and ORF1b. The re-
maining 3= one-third encodes the structural proteins spike (S),
envelope (E), membrane (M), and nucleocapsid (N) as well as
accessory proteins (encoded in ORF3 to ORF5 and ORF8b) that
are not required for genome replication but likely act as immune
antagonists that may be critical for pathogenesis (6–8). Indeed,
MERS-CoV and other CoVs induce type I interferon (IFN) only
weakly and late in infection (9–15), suggesting that coronaviruses
have evolvedmechanisms of immune evasion. Furthermore, there
are reports that MERS-CoV accessory protein NS4a (encoded by
ORF4a), NS4b (encoded by ORF4b), and NS5 (encoded by
ORF5), when overexpressed fromplasmids, antagonize type I IFN
induction and signaling at various points in the pathways (16–19).
NS4a is a double-stranded RNA (dsRNA) binding protein (17).
NS4b is detected primarily in the nucleus (16–19), making NS4b
and the severe acute respiratory syndrome coronavirus (SARS-
CoV) ORF3a-encoded proteins (20, 21) the only known corona-
virus proteins thus far to be detected in the nucleus (20, 21). A
MERS-CoVmutant with deletions of ORFs 3 to 5 is attenuated for
replication in human airway-derived Calu-3 cells (22), and a mu-
tant with deletions of ORFs 4a and 4b is attenuated for replication
in hepatic carcinoma-derived Huh-7 cells (23).
The type I IFN response is an essential component of antiviral
innate immunity and is initiated when host sensors initiate signal-
ing pathways resulting in transcription of type I IFN genes (9, 10,
24). IFN activates transcription of numerous IFN-stimulated
genes (ISG); among these and most relevant to this report are the
OAS genes (25). Oligoadenylate synthetase (OAS), upon detec-
tion and binding of dsRNA, synthesizes 2=,5=-oligoadenylate (2-
5A) [px5=A(2=p5=A)n; x  1 to 3; n  2] from intracellular ATP
that induces the homodimerization of latent RNase L, leading to
its subsequent activation (24, 26, 27). Activated RNase L cleaves
both viral and host ssRNA preferentially at UU and UA dinucle-
otide sequences, leading to translational arrest and apoptosis, and
limits viral replication and spread in vitro and in vivo (24, 28, 29).
In addition, RNA cleavage products can be recognized by RNA
sensors, leading to further augmentation of IFN production and
signaling (30).
We have shown previously that lineage A Betacoronavirusmouse
hepatitis virus (MHV) NS2 is a determinant of cellular and organ
tropism.MHVNS2 is a 2=,5=-phosphodiesterase (PDE) that antago-
nizes the type I IFN response by blocking activation of the OAS-
RNase L pathway and is a critical determinant of MHV hepatoviru-
lence (7, 29). Here we report that by structural homology,
biochemistry, and biological measures, MERS-CoV NS4b and ho-
mologs encoded by related bat lineage C Betacoronavirus, BtCoV-
SC2013 (SC2013) and BtCoV-HKU5 (HKU5), are also 2=,5=-PDEs
that can antagonize the IFN-inducible OAS-RNase L pathway.
RESULTS
Alignment and modeling of NS4b proteins. To elucidate the
function ofMERS-CoVNS4b, we queried the primary amino acid
sequence with theNational Center for Bioinformatics (NCBI) Ba-
sic Local Alignment Search Tool (BLAST). MERS-CoV NS4b was
found to have no primary amino acid sequence homology outside
of lineage C Betacoronavirus. To broaden the search for homolo-
gous proteins, we used tertiary structural prediction and homol-
ogy search by Phyre2 (31) and I-TASSER (32, 33). The top scoring
structure identified by both servers was the central domain of
Rattus norvegicusA kinase anchoring protein 7 isoform gamma or
delta (AKAP7/) (PDB: 2VFK), a 2H-phosphoesterase (2H-PE)
superfamilymember with 2=,5=-PDE activity (34) (Fig. 1A). These
enzymes are characterized by twoH--[ST]-motifs (where is
a hydrophobic residue) separated by an average of 80 residues
(35). To generate a more accurate predicted structure, the 2H-PE
domain of MERS-CoV NS4b was modeled directly on AKAP7
using one-to-one threading on Phyre2 followed by loop and side
chain refinement in Modeller (Fig. 1B) (29, 31). For comparison,
the recently solved structure of lineage A Betacoronavirus mouse
hepatitis virus (MHV) NS2, a 2H-PE with 2=,5=-PDE activity, is
also shown (Fig. 1C) (36).
MERS-CoV NS4b shares significant homology with closely re-
lated bat coronavirus (BtCoV) proteins encoded by SC2013 and
HKU5, 47% and 31% amino acid sequence homology, respectively.
While both BtCoV homologs have the 2 [H--(S/T)-] predicted
catalytic motifs, SC2013 NS4b (previously referred to as NS3c [37])
had low-confidence structural homology (45%) with AKAP7, and
HKU5NS4b had no significant structural homology with any struc-
tures in the Phyre2 database (38). However, alignment of the regions
surrounding theH--(S/T)-motifs with cellular AKAP7 from rat,
mouse (Mus musculus, NP_061217.3), and virus-encoded 2=,5=-
PDEs illustrates the conservation of these twomotifs (Fig. 2A).We
have previously shown that the central domain of theM.musculus
AKAP7 and simian rotavirus A (RVA), strain SA11, VP3 protein
carboxy-terminal domain (CTD) are catalytically active 2=,5=-
PDEs (28, 34, 35, 39). Additionally, MERS-CoVNS4b and BtCoV
homologs, like the rat and mouse AKAP7 but unlike any of the
known viral PDEs, including MHV NS2 or rotavirus VP3 CTD,
contain an amino-terminal nuclear localization signal (NLS)
FIG 1 Predicted structure of MERS-CoV NS4b phosphodiesterase. (A) Structure of Rattus norvegicus AKAP7/ (PDB: 2VFK) (37). (B) Tertiary structural
homology model of MERS-CoV NS4b. (C) Structure of NS2 (PDB: 4Z5V) (36). The structures were visualized and analyzed in UCSF Chimera 1.8.
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(Fig. 2B) (16, 18, 19). In addition to a PDE domain, AKAP7 also
contains a carboxy-terminal binding domain for the regulatory
subunit II (RII) of cyclic AMP (cAMP)-dependent protein kinase
A (PKA) (PKA-RII--BD) (39), and VP3 contains amino-
terminal guanylyltransferase (Gtase) and methyltransferase
(Mtase) domains (E) (28), neither of which are found adjacent to
coronavirus PDE domains.
NS4b from MERS-CoV and both BtCoVs are enzymatically
active 2=,5=-phosphodiesterases that cleave 2-5A. To determine
whether MERS-CoV, BtCoV-SC2013, and BtCoV-HKU5 NS4b
encode enzymatically active PDEs, NS4b genes were expressed in
Escherichia coli as maltose binding protein (MBP) fusion proteins
and purified by affinity chromatography followed by ion exchange
and size exclusion chromatography. Purified proteins were incu-
bated with various 2-5A substrate concentrations and subse-
quently used to assess enzyme kinetics via a fluorescence reso-
nance energy transfer (FRET)-based RNase L activation assay
(29). Substrate steady-state kinetic studies were performed (see
Materials and Methods for details), and the quantity of cleaved
2-5Awas determined as a function of time from 180-min progress
curves conducted in triplicate. The best-fit parameter estimates
are shown in Table 1. All three proteins were capable of cleaving
2-5A and preventing the activation of RNase Lwith similar kinetic
parameters to MHV NS2. As expected, mutant proteins contain-
ing a His-to-Arg mutation in the second catalytic motif were in-
capable of cleaving 2-5A (Fig. 3A). Although the activities of all
three NS4b proteins were similar to that of MHV NS2 (Fig. 3B),
velocities plateaued at lower concentrations of 2-5A compared with
MHV NS2, suggesting that the lineage C proteins become saturated
more quickly at higher 2-5A concentrations (Fig. 3C to E).
Expression of MERS-CoV NS4b and BtCoV homologs from
chimeric MHV. To investigate OAS-RNase L antagonism in cell
FIG 2 Cellular and viral 2=,5=-phosphodiesterase (PDE) domains. (A) Alignment of known and predicted cellular and viral 2=,5=-PDE sequences. Catalytic
motifs [H--(S/T)-] are indicated by the red and blue boxes. Rat (Rattus norvegicus [Rn]) andmouse (Musmusculus [Mm]) AKAP sequences and human (H)
and bat (Bt) coronavirus sequences are shown. (B) Comparison of known features of full-lengthM. musculus AKAP7, MHV NS2, RVA VP3 CTD and lineage
C NS4b proteins including nuclear localization sequence (NLS) and PDE domains. PKA-RII--BD, a binding domain for regulatory subunit (RII) of cAMP-
dependent protein kinase A (37), guanylyltransferase (Gtase), and methyltransferase (Mtase) domains are also indicated (32).
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culture, using the backbone of catalytically inactive NS2 with the
H126R substitution (NS2H126R) (MHVMut), we constructed chi-
meric MHVs that express one of the NS4b proteins, and for each
chimeric MHV, we constructed a corresponding catalytically in-
active mutant, each with a carboxy-terminal Flag tag (18, 34). In
addition, we constructed chimericMHVs expressingMERS-NS4b
with a deletion of the amino-terminal 52 amino acids including
theNLS (MHV-MERS1-52WT) as well as its catalytically inactive
mutant MHV-MERS1-52Mut. Thus, wild-type (WT) or mutant
NS4b genes were cloned into the MHVMut genome in place of
MHV ORFs 4a and 4b which encode protein(s) with no known
function in MHV replication or pathogenesis (40) (Fig. 4). To
assess expression of NS4b proteins from chimeric viruses, bone
marrow-derived macrophages (BMM) derived from mice genet-
ically deficient in RNase L (RNase L/) were infected with each
of the chimeric viruses in addition to WT MHV and MHVMut
expressing catalytically inactive mutant NS2. (RNase L/ BMM
were used rather than B6 BMM because an active PDE is required
for robust replication in the latter [29].) BMM were lysed at 12 h
postinfection, and protein lysates were analyzed by Western im-
munoblotting with antibodies directed against Flag to detect
NS4b proteins, antibodies against viral nucleocapsid to assess viral
replication, and antibodies against glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) as a loading and transfer control. All
NS4b proteins were expressed in RNase L/ BMM but to differ-
ent extents, and mutant NS4b proteins were expressed at lower
levels than WT NS4b proteins were, possibly reflecting reduced
protein stability as a result of the mutations (Fig. 5A). Similar
findings were obtained with chimeric virus infection of 17Cl-1
cells (data not shown).
All three NS4b proteins have an amino-terminal tripartite
NLS; previous studies reported thatMERS-CoVNS4b is predom-
inantly detected in the nucleus (41) and that overexpressed
BtCoV-HKU5 NS4b is solely detected in the nucleus (16). Previ-
ously, we found that murine AKAP7 was exclusively nuclear and
that it could not act as a PDE to rescue replication of chimeric
mutant MHV unless the NLS was removed and cytoplasmic ex-
pression was achieved (34), so it was important to determine the
subcellular localization of NS4b protein during chimeric virus in-
fection. Thus, immunofluorescence staining was carried out to
assess expression and subcellular localization of expression of each
NS4b protein.Murine L2 cells were infected with chimeric viruses
expressing both MERS-CoV NS4b and corresponding CoV ho-
mologs, fixed at 8 h postinfection, and stained with anti-Flag an-
tibodies (NS4b) and antibodies against the MHV nucleocapsid
protein, which is expressed in the cytoplasm (Fig. 5B). Interest-
ingly, MERS-CoV and BtCoV-SC2013 NS4b proteins localized to
the nucleus with expression in the cytoplasm as well, while the
BtCoV-HKU5 NS4b homolog was almost completely nuclear,
similar to reports of overexpressed NS4b in the literature (16–18).
As expected, MHV-MERS1-52WT expressing an NS4b with de-
letion of the NLS was localized to the cytoplasm.
TABLE 1 Enzyme kinetic parametersa
Enzyme
ppp5=A2=p5=A2=p5=A (2-5A substrate)
kcat (s1) Km (M) kcat/Km (M1 s1)
MHV NS2 3.9 0.4 6.7 1.6 0.6
MERS-CoV NS4b 2.1 0.2 2.6 0.6 0.8
SC2013 NS4b 2.4 0.1 2.9 0.6 0.8
HKU5 NS4b 1.9 0.1 1.3 0.3 1.4
a The enzyme kinetic parameters were determined by GraphPad Prism by the equation
Y Et kcat [X/(Km	 X)], where Y is the velocity of reaction in micromolar per
second, X is the substrate concentration in micromolar, and Et is the concentration of
enzyme catalytic sites. The kinetics were determined in triplicate reactions, and data are
expressed as means standard errors of the means.
FIG 3 Lineage C NS4b proteins are catalytically active 2=,5=-phospho-
diesterases. (A) Abrogation of catalytic activity by mutation of the second
catalytic His of NS4b proteins and comparison with MHVNS2 and RVA VP3
CTD. The kinetic data were obtained using 10 M 2-5A and 1 M enzyme
concentration with the exception of MBP, which was used at 10 M. Data
shown are from one representative experiment of three carried out with sep-
arate enzyme preparations. (B to D) Steady-state enzyme kinetic curves of
velocity versus concentration of 2-5A for MHV NS2 (B), MERS-CoV (C),
BtCov-SC2013 (D), and BtCoV-HKU5 (E) NS4b proteins. Kinetic reactions
were carried out in triplicate and expressed as means standard errors of the
means (SEM) (error bars). Substrate-dependent velocity measurements are
shown from one representative experiment carried out twice in triplicate with
separate enzyme preparations.
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NS4b proteins rescue replication of MHVMut in B6 BMM by
antagonizing RNase L. NS2 expression is necessary for robust
replication of MHV in BMM derived from B6 BMM (WT) but is
not required in RNase L/BMM(7, 29). To elucidate the roles of
the NS4b proteins in the context of viral infection, we inoculated
B6 BMMorRNase L/BMMwithwild-typeMHV (MHVWT) or
MHV expressing a catalytically inactive NS2 (MHVMut) as well as
chimeric MHVMut expressing either WT or mutant MERS-CoV
(both full-length and with amino acids 1 to 52 deleted) and
BtCoV-SC2013 NS4b proteins (see Fig. 4 for schematics of the
chimeric viruses). All three WT NS4b proteins, but not mutant
NS4b proteins, were able to rescue MHVMut replication in WT
BMM (Fig. 6A to D). Similar results were obtained for the pair of
viruses expressing BtCoVHKU5NS4b proteins (data not shown).
MHV expressing MERS-CoV WT NS4b (MHV-MERSWT) repli-
cated to a titer equivalent to that of WTMHV. Viruses expressing
the BtCoV homologs replicated well in B6 BMM but not quite to
the same extent as WT MHV or MHV-MERSWT, similar to find-
ings with the chimeric viruses expressing PDE of RVA VP3 CTD
and cellular AKAP7protein (28, 34) (Fig. 6D anddata not shown).
As expected, viruses expressing mutant as well as WT NS4b pro-
teins replicated to high titer in RNase L/ BMM. Although lo-
calization of NS4b proteins was primarily nuclear, these results
demonstrate that the level of expression of NS4b PDE at low levels
in the cytoplasm was sufficient to rescue replication in MHV-
MERS- and MHV-SC2013-infected B6 BMM.
rRNA degradation during infection is indicative of RNase L
activation, andwe have previously used this read out as an indirect
measure of RNase L activation (29). In addition, we previously
demonstrated that enzymatically active PDEs of RVA VP3 and
AKAP7, but not catalytically inactive mutant proteins, were capa-
ble of preventing rRNA degradation in B6 BMM during MHV
chimeric virus infection as determined by analyzing total RNA
levels postinfection on an Agilent bioanalyzer. Similarly, MHV-
MERSWT, both full-length andMHV-MERS1-52WTmutant and
MHV-SC2013WT clearly prevented RNase L-mediated RNA deg-
radation, while viruses expressing the inactive mutant proteins
activated the OAS-RNase L pathway. Surprisingly, BtCOV-
HKU5WT (expressed during MHV-HKU5WT infection) was un-
able to efficiently prevent rRNAdegradation despite the fact that it
did confer efficient replication in B6 BMM (data not shown). This
may be due to the mostly nuclear localization of MHV-HKU5WT,
which is discussed further below.
MERS-CoV NS4b rescues replication of MHVMut in vivo in
B6 mice. To determine whether MERS-CoV NS4b was capable of
rescuing replication ofMHVMut in vivo, we infected B6 and RNase
L/ mice with chimeric viruses expressing either MHV-
MERSWT or enzymatically inactive virus (MHV-MERSMut) and
compared replication to MHVWT. NS4b, but not NS4bMut, res-
cued MHVMut replication to MHVWT levels in B6 mice (Fig. 7).
Additionally, gross pathology was restored for MHV-MERSWT,
which is typically fully abrogated without an enzymatically active
NS2, but not forMHV-MERSMut (data not shown). This confirms
that MERS-CoV NS4b can act as an RNase L antagonist and con-
tribute to pathogenesis in vivo.
MERS-CoV inhibits rRNA degradation in a human airway
cell line. We constructed a MERS-CoV NS4b deletion mutant
(MERS-NS4b) andmock inoculated or inoculated a human air-
way epithelial cell line, Calu-3, with MERS-CoV, MERS-NS4b,
or MERS-CoV lacking NS3 to NS5 (MERS-NS3-5) (22). We
measured replication and rRNA degradation through the course
of a one-step growth curve. The characteristic signature of RNase
L activation in human cells is present during MERS-NS4b and
MERS-NS3-5 infections at late time points (Fig. 8A) and can be
FIG 4 Construction of NS4b-expressing recombinant MHV. (A) Diagrammatic representation of MHVMut genome (expressing catalytically inactive
NS2H126R). The letters designate genes encoding structural proteins, and the numbers designate ORFs encoding nonstructural proteins. ORFs 1a and 1b together
comprise 20 kb and are not to scale. (B) Wild-type or catalytic mutant NS4b genes are lined up with the MHV ORF4a or ORF4b insertion site to construct
chimeric viruses. Nuclear localization signals (NLSs) and phosphodiesterase (PDE) domains are indicated.
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quantified by Agilent RNA integrity number (RIN) and plotted
over time (Fig. 8B). The characteristic rRNA degradation signa-
ture is not present during MERS-CoV infection or mock infec-
tion. We observed no reduction in titer for MERS-NS4b but
nearly a 10-fold reduction in titer for MERS-NS3-5 compared
with wild-type MERS-CoV infection (Fig. 8C). Thus, while
MERS-CoV deletion mutants activate RNase L in Calu-3 cells,
rRNA degradation was not very extensive compared to that ob-
served in Sindbis virus infection of human A549 cells.
The more robust rRNA degradation seen with MERS-NS3-5
than with MERS-NS4b suggested that there may be additional
mechanisms of RNase L antagonism byMERS-CoV. In fact, NS4a
is a dsRNA binding protein that may help sequester viral dsRNA
and prevent stimulation of OAS and subsequent activation of
RNase L (17, 18). In addition, since NS4a and NS4b are expressed
from the samemRNA by an unknownmechanism of initiation of
translation, it is possible that deletion of ORF4b could result in
increased expression of the upstream ORF encoding NS4a and
increased dsRNA binding and inhibition of RNase L, negating the
need for a PDE to antagonize RNase L. Thus, we constructed
MERS-NS4bH182R, expressing NS4b with an inactive PDE, and
assessed its replication and ability to active RNase L inCalu-3 cells.
While MERS-NS4bH182R replicated similarly to WT MERS (data
not shown), it did promote RNase L degradation and like the
deletion mutants only at late times postinfection (Fig. 8D).
Thus,MERS-CoVNS4b and BtCoV homologs have 2=,5=-PDE
activity that antagonizes RNase L activation in vitro and is depen-
dent on a catalyticHis residue. In addition, likeMHVNS2, lineage
C BetacoronavirusNS4b activity is crucial for protection of rRNA
integrity and for efficient replication of chimeric MHV in cell
culture and in the case ofMERS-CoVNS4b, inmice.While RNase
L activation in Calu-3 cells is observed with both MERS-CoV de-
letion mutants, it is clearly less extensive than observed in the
chimeric MHV infections of BMM and has less effect on viral
replication as discussed below.
DISCUSSION
Herewedemonstrate thatMERS-CoVand relatedBtCoVNS4bpro-
teins inhibit the OAS-RNase L pathway by enzymatic cleavage of
2-5A, the activator of RNase L, potentially antagonizing IFN signal-
ing.The type I IFNresponse is an essential componentof the antiviral
innate immune response and is activated when host sensors detect
viral dsRNA, leading to production of type I IFN (9, 10, 24). IFN
activates transcription of IFN-stimulated genes (ISG), leading to the
development of an antiviral state in the infected cells and in neigh-
boring cells, thereby restricting viral spread. Based onoverexpression
experiments, it was previously reported that MERS-CoV NS4b and
HKU5NS4b proteins antagonize type I IFN signaling by several dif-
ferent methods, including interaction with Tank binding kinase 1
(TBK1)/IB kinase  (IKK), leading to inhibition of IFN regulatory
factor 3 (IRF3) phosphorylation, nuclear localization, and subse-
quent beta interferon (IFN-	) transcription (16, 18, 19). It was re-
cently shown by overexpression of NS4b and an IFN-	 promoter
reporter plasmid that MERS-CoV NS4b interacts with as yet un-
known nuclear targets inhibiting IRF3- and IRF7-induced IFN-	
transcription (19). It is important to note that there is little if any
information on IFN antagonism during MERS-CoV infection, and
none of these reports recognized the enzymatic activity of NS4b pro-
teins. Nevertheless, the previous publications in combination with
our current study of the enzymatic activity of NS4b proteins suggest
that NS4b proteins are multifunctional with activities in both the
cytoplasm and nucleus, consistent with its localization in both cellu-
lar compartments.
Searches for sequence homology betweenMERS-CoVNS4b in
protein databases were unsuccessful. However, NS4b was pre-
dicted by tertiary structural modeling to be a 2H-PE and the fact
that it is conserved in all sequenced lineage C Betacoronavirus
genomes suggested thatNS4b is an enzymatically active 2=,5=-PDE
(29), as confirmed in this study. Furthermore, NS4b protein an-
tagonizes the OAS-RNase L pathway by cleaving 2-5A and block-
ing the subsequent activation of RNase L (7, 29). Additionally,
closely related lineage C Betacoronavirus BtCoV-SC2013 and
BtCoV-HKU5 NS4b proteins are enzymatically active PDEs with
similar activity to MERS-CoV NS4b. We have demonstrated that
these lineage C proteins can cleave 2-5A in vitro and that their
kinetic parameters are similar to those of NS2.
FIG 5 Expression and localization of MERS-CoV NS4b and BtCoV ho-
mologs expressed by chimeric MHVs. (A) Lysates of chimeric-virus-infected
RNase L/ BMM were analyzed on denaturing polyacrylamide gels and an-
alyzed by immunoblotting with antibody against Flag (-Flag) to detect NS4b,
antibody against MHV nucleocapsid (N) protein, and antibody against
GAPDH. Data are representative of three experiments carried out twice in
17Cl-1 cells and once each in B6 and RNase L/ BMM with similar results.
(B) Murine L2 cells infected with chimeric MHVs were fixed and stained with
DAPI as well as antibodies against Flag to detect NS4b andMHVN. These data
are from one representative experiment of three.
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Limitation of RNase L activation can have a profound effect on
enhancing virus replication and spread as well as leading to de-
creased IFN production in myeloid cells (7, 29, 42). Indeed, we
previously found that the 2=,5=-PDEofMHVNS2 is a determinant
of myeloid cell tropism and a critical liver virulence factor in mice
(29). Thus, to initially assess the effectiveness ofNS4b proteins, we
utilized the chimeric MHV NS2 mutant virus system that was
previously used to demonstrate activity for RVA and AKAP PDEs
FIG 6 Lineage C PDENS4b proteins functionally replaceMHVNS2 in primary BMM. (A toD) Representative one-step growth curve ofWT andmutant (Mut)
MHV (A) and chimeric viruses expressing WT and mutant NS4b proteins (diagrammed in Fig. 4B), WT and mutant MHV-MERS (B), WT and mutant
MHV-MERS1-52 (C), andWT andmutant MHV-SC2013 (D) in B6 and RNase L/ BMM (MOI of 1 PFU; n 3). Statistical significance was determined by
two-way analysis of variance (ANOVA) with Sidak’s multiple comparisons and is indicated as follows: *, P value of0.05; **, P 0.01; ***, P 0.001. Values
that are not significantly different (ns) are indicated. Values are means  SEM (error bars). These data are from one representative experiment of three
experiments. (E) rRNA degradation pattern 15 h postinfection in B6 BMM. Data are from one representative experiment of three (MOI of 1 PFU; n 3). The
positions of 28S and 18S rRNAs are shown to the right of the gel.
MERS-CoV NS4b Is an RNase L Antagonist
March/April 2016 Volume 7 Issue 2 e00258-16 ® mbio.asm.org 7
(28, 34). Lineage C PDEs were expressed from chimeric MHV
with an NS2Mut background, encoding an inactive PDE. MERS-
CoV NS4b and BtCoV homologs were detected by immunoblot-
ting to different extents, as normalized to the amount of MHV
nucleocapsid protein detected, with the mutant proteins less well
expressed compared to WT proteins. The different levels of ex-
pression of WT proteins and the more efficient expression of the
WT PDEs compared to the corresponding mutant proteins was
observed in both BMM and murine 17Cl-1 fibroblasts (Fig. 5 and
data not shown), suggesting that there may be differences in sta-
bility in theWT proteins and that the mutant proteins may be less
stable. Nevertheless, we were able to rescue replication in murine
BMM with wild-type MHV-MERS, wild-type BtCoV-2013
(Fig. 6), and wild-type BtCoV-HKU5 (data not shown) but not
with viruses expressing corresponding mutant PDEs and in the
case of MHV-MERSWT, but not MHV-MERSMut, in vivo in the
mouse liver as well. Since theNS4b catalyticmutants used here are
poorly expressed, they do not provide the ideal control and we
cannot rule out the possibility that either one or more would res-
cue at a higher expression level or that factors other than the PDE
activity contribute to rescue. This, however, is highly unlikely, as
we know from several previous studies (28, 29, 34) that efficient
expression of catalytic mutant PDE does not rescue replication of
MHV NS2 mutant virus, while supplying with heterologous PDE
does (28, 29, 34).
We have previously demonstrated that cytoplasmic localiza-
tion of PDE activity is necessary to antagonize the OAS-RNase L
pathway.Murine AKAP7, which contains anNLS, can rescue only
chimeric PDE-deficient MHV in the absence of the NLS (34).
Interestingly, it is unnecessary to remove the NLS from theMERS
and SC2013 NS4b proteins to achieve rescue of chimeric MHV,
and in fact, removal of the N-terminal 52 amino acids, including
the NLS, of MERS-CoV NS4b confers no replication enhance-
ment (Fig. 6), suggesting that the NLS neither hinders nor im-
proves OAS-RNase L antagonism. Recombinant HKU5 NS4b
clearly has 2=,5=-PDE activity (Fig. 3), and MHV-HKU5WT (but
FIG 7 Catalytically active MERS-CoV NS4b rescues replication of MHVMut
in the livers of B6mice. Liver titers (n 19 or 20) day 5 postinfection (MOI of
2,000 PFU) of MHVWT and MHVMut (A) or MHV-MERSWT and MHV-
MERSMut (B). Statistical significance was determined by 
2 test with Yates’
correction and is indicated as follows: *, P value of 0.05; ***, P  0.001.
Values are means SEM (error bars). Values that are not significantly differ-
ent (ns) are indicated. These data are pooled from four experiments
FIG 8 MERS-CoV inhibits rRNAdegradation in human airway cells. (A to C)
rRNA degradation pattern from cells 36 h postinfection (A), quantification by
RNA integrity number (RIN) (B), and replication kinetics (C) of mock-
infected and MERS-CoV-, MERS-NS4b-, and MERS-NS3-5-infected
Calu-3 cells (MOI of 1 PFU; n 3). Statistical significance was determined by
two-way ANOVAwith Sidak’s multiple comparisons and indicated as follows:
***, P value of 0.001; ns, not significant. Values are means  SEM (error
bars). RNA from Sindbis virus-infected human A549 cells (run separately on
the Agilent Bioanalyzer) is shown in panel A as a marker for the RNase
L-induced pattern of degradation of human rRNA. (D) rRNA degradation
pattern from cells 24 and 48 h afterMERS-NS4bH182R infection of Calu-3 cells.
The positions of 28S and 18S rRNAs are indicated in panels A and D. Data
shown are from one representative experiment of two.
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not MHV-HKU5Mut) clearly replicates efficiently in B6 BMM
(data not shown), demonstrating thatHKU5NS4b can replace the
function of NS2 in the MHV chimeric background. However,
therewas still detectable RNAcleavage in BMMinfectedwith both
MHV-HKU5WT and MHV-HKU5Mut (data not shown). The
most likely explanation is that BtCoV-HKU5 NS4b does not an-
tagonize RNase L activation as well as MERS-CoV or BtCoV
SC2013 NS4b does, because it is more localized to the nucleus,
consistent with our findingswith the PDEof AKAP7 (34). It is also
possible the rRNA is more susceptible to cleavage than viral RNA;
therefore, the less effective BtCoV-HKU5 NS4b cannot antago-
nize RNase L effectively enough to spare rRNA while still protect-
ing viral and/or cellular mRNA.
We have demonstrated that MERS-CoV antagonizes OAS-
RNase L activation in Calu-3 cells and that mutant viruses with
deletions of either NS3 to NS5 or NS4b alone as well as the cata-
lyticmutantMERS-NS4bH182R activate this pathway. Although all
mutants induced rRNA degradation, only MERS-NS3-5 had a
reduction in viral titer by 24 h postinfection. Thus, the lack of
effect on replication of MERS-NS4 or MERS-NS4bH182R corre-
lates with the weak rRNA degradation observed and indicates a
lack of biological effect in this cell type of deleting or inactivating
the NS4b PDE. This may be due in part to the very late times
postinfection (24 to 48 h) that we observe rRNA degradation;
virus replication is already quite robust by that time, and itmay be
too late for restriction of replication to occur.
We have found previously that cell type is critical for robust acti-
vation of RNase L and reduction in viral titers during infection of
murine cells and have observed activation of RNase L by MHVMut
only in myeloid cells (43) and endothelial cells (unpublished data).
The use of Calu-3 epithelial airway cells may explain the lack of re-
striction ofMERS-NS4b replication and only 10-fold reduction for
MERS-NS3-5, when in murine BMM, abrogation of RNase L an-
tagonism by MHV, which is observed by 9 h postinfection, leads to
100- to 1,000-fold reduction in viral titers. Indeed, RNase L is not
readily activated in Calu-3 cells compared to other cell types; the
amount of rRNA degradation observed in Sindbis virus-infected
A549cells is clearlymore than inCalu-3cells (Fig. 8A), andwedidnot
observe robust activation of RNase L Calu-3 cells even when trans-
fected with the dsRNA surrogate poly(I · C) (data not shown). Fur-
ther studies are being directed at identifying a cell type in which PDE
activity enhances viral replication.
MATERIALS AND METHODS
Cell lines and mice. Murine L2 (L2) and baby hamster kidney cells ex-
pressing MHV receptor (BHK-MHVR) were cultured as described previ-
ously (7, 44). Calu-3 clone 2B4 cells (a kind gift from Chien-Te Tseng,
University of Texas Medical Branch, Galveston, TX) were cultured with
Gibco minimum essential medium (MEM) (Thermo Fisher Scientific,
Grand Island, NY) supplemented with 20% fetal bovine serum (FBS)
(HyClone, GE Healthcare Bio-Sciences, Pittsburg, PA), penicillin-
streptomycin (Gibco), and amphotericin B (Fungizone) (Gibco). Vero
CCL-81 cells (ATCC, Manassas, VA) were cultured, and the MERS-CoV
plaque assay was performed as previously described (22). Human A549
cells were cultured in RPMI 1640 medium (Gibco) supplemented with
10% FBS, 100 U/ml of penicillin, and 100 g/ml streptomycin. All cells
weremaintained at 37°C and 5%CO2. B6mice andRNase L/micewere
bred andmaintained in theUniversity of Pennsylvania animal facility, and
the protocols were approved by the Institutional Animal Care and Use
Committee at theUniversity of Pennsylvania. Primary BMMwere derived
from bone marrow harvested from the hind limbs (tibia and femur) of 4-
to 6-week-old B6 or RNase L/mice and described previously (29, 45).
Cells were cultured in Dulbecco modified Eagle medium (DMEM)
(Gibco) supplemented with 10% FBS (HyClone) and 20% L929 cell-
conditioned media for 6 days before infection.
Plasmids and recombinant viruses.NS4b sequences for MERS-CoV
(GenBank accession no. AFS88939.1), SC2013 (GenBank accession no.
AHY61340.1), andHKU5 (accession no. YP_001039965.1) were obtained
fromNCBI.NS4bcDNAsequenceswere synthesizedwith the additionof a 5=
SalI site and 3= Flag epitope and NotI site and then cloned into pUC57 (Bio
Basic, Markham, Ontario, Canada). Site-directed mutagenesis was per-
formed on each NS4b plasmid to generate point mutants (CAC to CGC)
containing histidine-to-argininemutations within the second catalytic motif
yielding H182R, H186R, and H183R for MERS-CoV, SC2013, and HKU5
NS4b proteins, respectively, and subsequently sequence verified. Each NS4b
gene was then PCR amplified and subcloned in frame with maltose binding
protein into pMALprotein expression vector.MHVNS2 andNS2H126Rwere
previously cloned into pMAL parallel-2 vector (29).
MHVWT,MHVMut, and all chimeric viruses were constructedwith the
MHV strain A59 infectious clone (44). Each WT or mutant NS4b cDNA
was subcloned into open reading frame 4 (ORF4) of the infectious clone
plasmid GEGFP (EGFP stands for enhanced green fluorescent protein),
and sequences were confirmed as described previously (28). The full-
length cDNAswere assembledwithA to E (MHVWT), F (MHVMut), andG
(NS4b) fragments, and RNA was in vitro transcribed and recovered as
previously described (44). Briefly, infectious clone fragments were excised
from their respective plasmids by restriction enzyme digestion. The frag-
ments were gel purified and ligated in vitro to create a full-length cDNA.
cDNA was in vitro transcribed with mMessage mMachine T7 transcrip-
tion kit (Ambion; Thermo Fisher, Grand Island, NY), generating full-
length genomic RNA. Each genomic RNA transcript was split into two
distinct pools and electroporated into BHK-MHVR along with N-protein
transcript using Gene Pulser II (Bio-Rad, Hercules, CA). Electroporated
cells were incubated until cytopathology was evident throughout, freeze
thawed three times, and plaque purified, and one plaque from each pool
was utilized in parallel for all assays.
MERS-NS4b was constructed using the MERS-CoV infectious clone
(22). To delete NS4b, sequence was synthesized (Bio Basic) in which muta-
tions were made in the overlap region between NS4a and NS4b to abrogate
putative start codons (T2C andT17C; all positions relative to theNS4b start)
and to insert premature stop codons (A91T, C97A, and C102G). Addition-
ally, residues106 to669weredeleted toremove themajorityofNS4bbut leave
in place transcriptional regulatory sequence 5. The truncated NS4b cassette
and MERS-CoV infectious clone F plasmid were digested with PacI and
SanDI, and truncated NS4b was ligated into the MERS-CoV F plasmid. To
construct theMERS-NS4bH182Rmutant, twoPCRswereperformedusing the
F plasmid as the template to synthesize overlapping DNA fragments and
introducing anH182R substitution. These two templates were then joined in
an overlapping extension PCR. The resultant product was digested with PacI
and SanDI and cloned into the MERS F plasmid. Assembly of the infectious
clone and recoveryof infectious viruswereperformedasdescribedpreviously
(22). The potential gain-of-function (GOF) concerns of MERS-NS4b and
MERS-NS4bH182R were evaluated and reviewed by NIH under grant
U19AI107810 and approved for continued study. The MERS-NS3-5 mu-
tant (22) was generated prior to GOF regulations. The MERS-NS3-5 and
catalytic mutant display attenuated growth on select interferon-competent
human cell lines.
FRET assay and enzyme kinetics. NS4b of MERS-CoV, SC2013, and
HKU5were cloned intopMalparallel-2 vector (46) andexpressed inBL21T7
express competent E. coli (NEB, Inc., Ipswich, MA) as maltose binding pro-
tein (MBP) fusionproteins andpurifiedbyaffinity chromatography followed
by ion exchange chromatography onMonoQGL10/100 using a NaCl gradi-
ent from 0 to 1 M in 20 mM HEPES (pH 7.2) and gel filtration in 20 mM
HEPES (pH 7.2) containing 100 mMNaCl as described earlier for purifica-
tion ofMHVNS2 (29). Briefly, purified proteins (10MMBP as control or
1 M concentration of MBP fusion proteins with NS4b of MERS-CoV,
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SC2013, and HKU5 or their catalytically inactive mutants described in the
previous section) in 150l of assay buffer (20mMHEPES [pH 7.2], 10mM
MgCl2, 1mMdithiothreitol)were incubated at 30°Cwith various concentra-
tions of (2=-5=)p3A3. Aliquots of 20l werewithdrawn at different times, and
the reactionswere stopped by heat inactivation at 95°C for 3min followed by
30-min centrifugation at 20,000 g (4°C) and supernatants were carefully
removed. A fluorescence resonance energy transfer (FRET)-based RNase L
activation assay was used to determine enzyme kinetics by measuring the
uncleaved, intact (2=,5=)p3A3 as previously described (47). The amounts of
2-5A cleavedwere determined by the relative fluorescence units (RFU) using
standardcurveswithdifferent concentrationsof authentic 2-5A.The reaction
velocities were determined by nonlinear fit of the data. The kcat andKmwere
determined in GraphPad Prism 5.0 forWindows by plotting velocity against
substrate concentrations, and data were analyzed by the following equation:
Y  Et  kcat  [X/(Km 	 X)], where Y is the velocity of the reaction in
micromolar per second,X is the substrate concentration inmicromolar, and
Et is the concentrationof enzymecatalytic sites.Thekineticsweredetermined
in triplicate reactions.
In vitro infections. (i) Chimeric MHV infections. BMM were mock
inoculated or inoculated with MHVWT, MHVMut, MHV-MERSWT,
MHV-MERSMut, MHV-SC2013WT, MHV-SC2013Mut, MHV-HKU5WT,
or MHV-HKU5Mut. Virus was added to cells at a multiplicity of infection
(MOI) of 1 PFU/cell and allowed to adsorb for 1 h at 37°C. Cultures were
washed with phosphate-buffered saline (PBS) (three times) and fed with
medium. At the times indicated in the figures, cells were fixed and ana-
lyzed for protein expression by immunofluorescent staining, lysed, and
analyzed for protein expression by immunoblotting or analyzed for deg-
radation of RNA, or supernatants were harvested for quantification of
viral titers by plaque assay on L2 cells (48).
(ii) MERS-CoV infections of Calu-3 cells. Prior to infection, Calu-3
cells were washed once with PBS (Gibco) to remove residual fetal bovine
serum (FBS). Cells were inoculated under biosafety level 3 (BSL3) condi-
tions with MERS-CoV, MERS-NS4b, MERS-NS4bH182R, or MERS-
NS3-5 at anMOI of 1 PFU/cell and allowed to absorb for 40min at 37°C.
The inoculum was then removed, and the cells were washed twice with
PBS prior to adding media containing low FBS (4%). At the time points
indicated in the figures, 100l of mediumwas collected and subsequently
analyzed by plaque assay in Vero CCL-81 cells as previously described
(22), and total RNA was harvested in 1 ml Trizol.
Immunoblotting. At 12 h postinfection, cells were lysed in Nonidet
P-40 (NP-40) buffer (1% NP-40, 2 mM EDTA, 10% glycerol, 150 mM
NaCl, and 50 mM Tris [pH 8.0]) containing protease inhibitors (Roche).
Protein concentrations were measured using a DC protein assay kit (Bio-
Rad). Supernatants were mixed 3:1 with 4 SDS-PAGE sample buffer.
Sampleswere boiled, separated by 4 to 15%SDS-PAGE, and transferred to
polyvinylidene difluoride (PVDF) membranes. Blots were blocked with
5% nonfat milk and probed with the following antibodies: anti-Flag M2
mousemonoclonal antibody (Agilent) (1:1,000), anti-Nmousemonoclo-
nal antibody (a gift from Julian Leibowitz) (1:400), and anti-GAPDH
mouse monoclonal antibody (Thermo Fisher Scientific) (1:1,000). Anti-
mouse secondary antibodies labeled with horseradish peroxidase (HRP)
(Santa Cruz; 1:5,000) were used to detect the primary antibodies. The
blots were visualized using SuperSignal West Dura extended-duration
substrate (Thermo Scientific). Blots were probed sequentially with anti-
bodies with the blots stripped between antibody treatments.
Indirect immunofluorescence assay. L2 cells were infected at anMOI
of 1 PFU/cell for 8 hwithMHVWT,MHV-MERSWT,MHV-SC2013WT, or
MHV-HKU5WT. Cells were washed with Dulbecco’s phosphate-buffered
saline (DPBS) (Gibco) and thenfixedwith 4%paraformaldehyde inDPBS
(Gibco). After fixation, cells were permeabilized with 0.1% Triton in
DPBS (Gibco) and then blocked with bovine serum albumin. Cells were
then stained with mouse monoclonal anti-nucleocapsid (1:200) and rab-
bit anti-Flag polyclonal (Sigma) (1:2,000) antibodies. After the cells were
washed, secondary staining with Alexa Fluor 488-labeled goat anti-mouse
(1:400) and Alexa Fluor 594-labeled goat anti-rabbit (1:1,000) antibodies
was performed. The cells were washed once more, and the nuclei were
then stained with 4=,6=-diamidino-2-phenylindole (DAPI). Stained cells
were imaged at a magnification of400 on an Eclipse TE2000-U fluores-
cence microscope (Nikon Instruments, Inc.). Images were acquired using
NIS-Elements Basic Research microscope imaging software (Nikon In-
struments, Inc.). This was performed at least twice for all viruses.
Qualitative and quantitative analyses of RNase L-mediated rRNA
degradation. RNA from B6 BMM infected with MHVWT, MHVMut,
MHV-MERSWT, MHV-MERSMut, MHV-SC2013WT, MHV-SC2013Mut,
MHV-HKU5WT, or MHV-HKU5Mut was harvested with an RNeasy kit
(Qiagen, Valencia, CA) 15 h postinoculation. Alternatively, Calu-3 cells
infected with MERS-CoV, MERS-NS4b, MERS-NS3-5, or MERS-
NS4bH182R, and at the time points indicated in the figures, RNA was
harvestedwithTrizol (SigmaAldrich, St. Louis,MO), extractedwith chlo-
roform (Sigma), and precipitated with isopropanol (Sigma). RNA was
then separated and analyzed on RNA nanochips with an Agilent Bioana-
lyzer 2100 (Agilent Technologies, Santa Clara, CA), and the pseudogels
were normalized for concentration (49). RNA integrity numbers (referred
to as RIN values) (50) are measurements of RNA integrity produced by
the Agilent Bioanalyzer. RNA from A549 cells infected with Sindbis virus
(51) was used as a marker for the pattern of human RNase L-dependent
rRNA cleavage products.
Inoculation of mice. Four-week-old B6 or RNase L/ mice were
anesthetized with isoflurane (Abbott Laboratories, Chicago, IL) and inoc-
ulated intrahepatically with MHVWT, MHVMut, MHV-MERSWT, or
MHV-MERSMut in 50 l of DPBS (Gibco) containing 0.75% bovine se-
rum albumin (Sigma). Mice were humanely euthanized with CO2 and
perfused with DPBS (Gibco), and their livers were harvested at day 5
postinoculation. Viral titers were determined by plaque assay of lysates
(48). This study was carried out in strict accordance with theGuide for the
Care and Use of Laboratory Animals (41) and the Public Health Service
Policy on Humane Care and Use of Laboratory Animals (52).
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